Safety Thumbs Up For Zynteglo Prompts Bluebird To Lift Marketing Suspension
US Filing For The β-Thalassemia Gene Therapy Is On Track
No evidence has been found linking the viral vector in bluebird’s gene therapy for β-thalassemia to blood cancer, the European Medicines Agency says.
You may also be interested in...
The FDA placed a partial hold on its clinical program for lovo-cel due to an adolescent patient experiencing anemia 18 months after treatment, raising uncertainty over filing plans.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.
bluebird bio's decision to wind down commercial initiatives for its gene therapy business in Europe is a blow for the sector in the region as a whole.